Outcome of Board Meeting held today i.e. May 22, 2026.
TRUALT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
TruAlt Bioenergy reported FY2026 standalone revenue of Rs 1,704.65 crore, down 9.3% from Rs 1,880.12 crore in FY2025. Standalone PAT fell to Rs 80.03 crore from Rs 140.62 crore (43% decline), with EPS at Rs 10.23 vs Rs 20.08 prior year. Consolidated PAT was Rs 96.87 crore. The company completed its IPO in September 2025 (oversubscribed 75 times), raising Rs 665.71 crore. Post-IPO, it deployed Rs 420 crore for capex and Rs 425 crore for working capital. Operating cash flow turned sharply negative at Rs (2,961.50) crore vs positive Rs 3,353.23 crore in FY2025 due to inventory buildup (Rs 3,176.25 crore increase) and trade payables reduction. Borrowings increased to Rs 1,580.46 crore from Rs 1,532.45 crore. Statutory auditor issued an unmodified opinion but included an Emphasis of Matter regarding pending componentization of dual-feed expansion assets under Ind AS 16.
Revenue and profit declined year-on-year due to seasonal raw material constraints and higher working capital needs, though IPO proceeds provide funding flexibility. Negative operating cash flow is a concern but is partially attributed to strategic inventory buildup ahead of extended supply commitments. Clean audit opinion reduces going-concern risk.